FSCN1 and neoplasm: Altogether, our results confirm the necessity of performing comparative, in-depth in vivo studies employing distinct Fscn1 inhibitors and subsequent ex vivo analysis to delineate, in detail, by which mechanisms these may inhibit tumor growth.